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characteristics. The checklist suggests that a quality network meta-analysis of 
this data should exclude one study with high risk of bias, avoid grouping sham 
procedures and optimal pain management, and control for baseline pain-score 
to address imbalance across arms. Meta-regression to control for differences in 
endpoint definitions or inclusion criteria would likely have been infeasible given 
the low number of studies. ConClusions: Applying the checklist improved our 
ability to identify sources of confounding to be addressed or highlighted as caveats 
in a meta-analysis.
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IMPleMentatIon of InteRnatIonal ChaRt RevIew StudIeS: an 
aSSeSSMent of Key deSIgn and oPeRatIonal ConSIdeRatIonS foR 
SuCCeSSful ConduCt
Jean-Mary J.1, Stein D.2, Payne K.A.2
1Evidera, Hammersmith, UK, 2Evidera, Dorval, QC, Canada
objeCtives: There is an increased need to conduct international chart review 
studies (chart reviews) since health care databases with required information are 
not consistently available. Chart reviews offer an alternative for the effective cap-
ture and analysis of real-world patient-level data on patient characteristics and 
outcomes, treatment patterns, treatment effectiveness and safety. For successful 
implementation, awareness of significant multi-national design and operational 
considerations is necessary. Methods: A critical review of 13 recent chart reviews 
conducted in Europe and North America on treatment patterns, clinical outcomes 
and/or drug utilization and safety was undertaken. Design and operational chal-
lenges, opportunities, and learnings are delineated. Results: All studies collected 
data retrospectively. Two studies collected certain information prospectively. Four 
studies were categorized as post authorization safety studies. Therapeutic areas 
varied across the studies with 8 studies being in oncology. Sample size ranged 
from 20-2,000 patients, number of countries ranged from 1-6, and number of sites 
ranged from 4-375. All studies included at least 1 European country. Across studies, 
key design considerations include confirming the eligibility and study periods that 
permit evaluations of recent care patterns yet allow for sufficient follow-up time, 
case ascertainment and sampling frame methodologies, and safety reporting in the 
context of retrospective source data. Additionally, key operational considerations 
include balancing science and practicality in site selection, ambiguous multina-
tional ethical/regulatory requirements, country variations for informed consent, 
data collection designed to minimize site burden, and effective yet cost-efficient site 
management for quality data. ConClusions: International chart reviews are prov-
ing to be an effective methodology for capturing tailored, patient-level data. These 
studies can be used to address a myriad of research objectives. Through conduct 
and assessment of recent chart reviews, the design and operational considerations 
involved can be understood with opportunities for improvement learned. These 
lessons will help for better planning and overcoming these challenges.
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geneRatIng and MaIntaInIng MoMentuM In PoSt-authoRISatIon 
StudIeS
Vinken A.1, Lis Y.2, Coward G.2
1PAREXEL International, Amsterdam, The Netherlands, 2PAREXEL International, Uxbridge, UK
objeCtives: Some observational studies fail to gain momentum while others move 
smoothly to successful completion. This study set out to determine which factors 
drive physician motivation in prospective observational studies. Methods: A web 
based survey was designed using input from structured literature review, investiga-
tors and experienced observational study researchers. It comprised 35 questions 
covering: Scientific and clinical factors (7), Study requirements (11), Operational 
considerations (6), Financial and legal considerations (4), Personal and professional 
factors (7). Respondents were asked to rate factors on a scale -5 to +5 (+5 represented 
very motivational and -5 very de-motivational). Free form comments were also 
invited. The survey was e-mailed to investigators (n= 1160) identified from Citeline® 
as having performed both prospective observational studies and clinical trials in the 
last 5 years. Results: Overall response was 15% (n= 174), Europe (55%) and North 
America (45%) covering Community care (34%), University hospitals (29%), General 
hospitals (24%) and dedicated research facilities (13%). Most respondents had experi-
ence of > 5 clinical trials in the last 5 years (81%) but fewer had similar experience 
with observational studies (40%). Responses indicate that not all physicians are 
equally motivated by the same factors. However most important motivational fac-
tors were in the scientific and clinical, financial and legal domains including studies 
which advance medical knowledge and / or patient management and acceptable 
honoraria. Less important factors were in the personal and professional domain 
including opportunities to speak at conferences or publish the data. Investigators 
more experienced in observational research placed greater motivational value on 
advancing medical knowledge and/ or patient management than less experienced 
colleagues. ConClusions: The findings provide good insight into which factors 
really motivate physicians and more customised motivational approaches are likely 
to minimise study risks. Further sub analyses of the survey data may identify more 
detailed strategies to pursue.
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ReSeaRCh In haeMoPhIlIa B – StudIeS In a RaRe dISeaSe In tIMeS of 
RequIReMentS foR hIgh evIdenCe levelS
Schopohl D.1, Berger K.1, Schramm W.2
1University Hospital of Munich, Muenchen, Germany, 2Rudolf-Marx-Stiftung, Bluterbetreuung 
Bayern, Muenchen, Germany
objeCtives: Haemophilia B (HB), a rare disease, occurs in approximately 1:30,000 
males and requires individualized therapy with factor IX (FIX) concentrate. Payers 
in European countries request studies with high levels of evidence for decision 
making. The objective was to determine the status quo of current studies con-
cerning HB, new FIX products and new therapeutic modalities regarding clinical 
and real-life evidence. Methods: A systematic literature research was conducted 
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novel uSe of MultIvaRIate JoInt ModellIng to IdentIfy PatIent level 
faCtoRS aSSoCIated wIth tReatMent faIluRe – exaMPle of Botox 
tReatMent foR PatIentS wIth oveRaCtIve BladdeR
Owen R.K., Crowther M.J., Tincello D.G., Abrams K.R.
University of Leicester, Leicester, UK
Detrusor overactivity (DO) is characterised by the symptoms of overactive bladder 
(OAB) including incontinence, urgency, and voiding episodes; though, identifica-
tion of a cardinal symptom still remains unclear, where treatment efficacy is often 
evaluated across multiple outcomes. As a result, ascertainment of the most patient 
impacting symptom is crucial. Joint modelling allows us to evaluate the association 
between surrogate outcome measures such as patients’ symptom profiles and time 
to perceived treatment failure. objeCtives: To determine the most associated OAB 
symptom with patients’ perceived time of treatment failure using a novel applica-
tion of a joint modelling framework. Methods: To account for the potential cor-
relation between symptoms, we applied a joint model of multivariate longitudinal 
and time-to-event data to a randomised clinical trial of patients receiving botulinum 
toxin for DO. We investigate the association of incontinence, urgency and voiding 
episodes collected at baseline, 6 weeks, 3 months, and 6 months, on patients’ per-
ceived time of treatment failure. Results: The multivariate joint model was applied 
to 122 patients (270 data points) with 69 (56.6%) patients reporting treatment failure. 
The results identified urgency as the most impactful surrogate measure on patients’ 
perceived time of treatment failure, with an estimated hazard ratio of 1.26 (95% CI: 
0.97 to 1.64) for every additional urgency episode. Incontinence, voiding episodes 
and the interaction between symptom measures had a non-significant association. 
However, in this example, sensitivity to the model choice produced inconsistent 
estimates due to the limited nature of the data set and therefore results should be 
interpreted cautiously. ConClusions: This approach illustrates the advantage of 
applying a joint modelling framework to identify symptoms most associated with 
time to treatment failure. With an increasing need to identify and assess core symp-
toms for varying medical conditions, the novel use of a joint modelling approach 
would appear to be extremely promising.
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uSIng MultI-CRIteRIa deCISIon analySIS to SuPPoRt alloCatIon 
deCISIonS In laRge tRanSlatIonal ReSeaRCh PRoJeCtS
De Graaf G., Postmus D.
University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
objeCtives: Large translational research projects often have abstract objectives, 
such as reducing the burden of disease and health care costs from type-2 diabetes 
(T2DM). Such an abstract objective entails: i) a very large number of possible strate-
gies to reach the objective and ii) a lack of detailed data and high levels in uncer-
tainty. Currently, no methods to support project selection and resource allocation 
decisions in such a setting are available. Methods: As a case study, we supported 
a resource allocation decision for the remaining funds in a large Dutch translational 
research consortium with the aforementioned objective, and compared the results 
to the decision made at the start of the project. We used the problem structuring, 
model building methods from multi-criteria decision analysis to identify four dif-
ferent alternative research strategies, and a set of evaluation criteria. Consequently, 
we used a combination of judgment from experts involved in the project and pre-
viously published data on the burden of disease and health care costs to evalu-
ate the alternatives. Finally, a decision analysis was performed using Stochastic 
Multicriteria Acceptability Analysis for ordinal data (SMAA-O), which allows for 
the combined use of quantitative and qualitative (ranked) data. Results: Using 
our method, it was decided to allocate remaining resources to the identification of 
biomarkers and development of technologies that can be used in the prevention of 
macrovascular complications in T2DM patients. This decision differed from the one 
made at the start of the project, which was not supported by any formal decision 
analysis. ConClusions: Our study shows that our method using SMAA-O can be a 
practical and valuable tool to support decisions on the allocation of research funds 
within large translational research consortia.
ReSeaRCh on MethodS – Study design
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ConfRontIng heteRogeneIty: uSIng SySteMatIC RevIew effeCtIvely 
foR Meta-analySIS
Quigley J.M., Woods B., Thompson J., Bryden P.A., Scott D.A.
Oxford Outcomes Ltd., Oxford, UK
objeCtives: The pooling of treatment effects estimated from several trials via 
meta-analysis or network meta-analysis can be confounded by differences across 
studies; however, advanced methodologies are available to address many of these 
issues. Systematic reviews of interventions typically generate a large volume of 
data and lead to assimilation of a large amount of knowledge by the reviewers. 
Identifying key variances between trials can be difficult and important nuances 
can be missed by a meta-analyst. We have designed a novel checklist that high-
lights key areas of heterogeneity to be considered when designing and undertaking 
meta-analysis. Methods: It is important to identify differences early on; hence 
we have developed a checklist that can be applied to the results of a systematic 
review of randomised controlled clinical trials. Components of the checklist fall 
into four domains where heterogeneity may be present: population, interventions, 
outcomes, and risk of bias. Sections documenting the feasibility of network meta-
analysis and recommendations for analysis design are also included. The checklist 
has been retrospectively applied to a recent NICE technology appraisal; percuta-
neous vertebroplasty and percutaneous balloon kyphoplasty for the treatment 
of osteoporotic vertebral compression fractures (TA279). Results: The checklist 
identified the following sources of heterogeneity in the nine included studies: 
inclusion criteria, endpoint definitions, endpoint reporting, presence of cross-over, 
differences in interventions, risk of bias; and within-trial imbalances in baseline 
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Assessment, Development and Evaluation) Methods: We evaluated the primary 
endpoint of a random sample from efficacy and effectiveness studies included in 
a systematic review on the treatment of rheumatoid arthritis with anti-TNFs. The 
quality assessment was conducted in accordance with the recommendations of the 
GRADE Working Group available at: www.gradeworkinggroup.org/toolbox/index.
htm. It assigns at first high quality for trials and low quality for observational stud-
ies. Results: The assessment of 8 efficacy and 8 effectiveness studies showed 
respectively that the quality of evidence were high in 5 and 0; moderate in 3 and 
2; low in 0 and 2; and very low in 0 and 4. The risk of bias was present in 3 and 5; 
imprecision results in 0 and 5; elevated magnitude of effect in 6 and 4; controlled 
confounding bias in 0 and 3; presence of dose-response gradient in 0 and 1. Indirect 
evidence and inconsistencies were not found in any of the studies. ConClusions: 
The quality of evidence of 3 trials and 4 observational studies were downgraded, while 
2 observational studies had the quality assessment increased.
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what value Can oPeRatIonal feaSIBIlIty StudIeS BRIng to PoSt 
MaRKetIng oBSeRvatIonal StudIeS (PMoS)? exaMPle of feaSIBIlIty 
Study PeRfoRMed In eaSteRn euRoPe to aSSeSS hePatItIS C vIRal 
dISeaSe/PatIent ManageMent In Real woRld SettIng
El Kebir S., Bayle D., Gauchoux R.
Mapi, Real World Evidence, Lyon, France
objeCtives: Operational feasibility studies provide a good opportunity to assess 
practicality of large full-scale studies. They are an almost essential pre-requisite and 
should be well designed with clear objectives. Conducting a pilot study can enhance 
the likelihood of success of PMOS and potentially help to avoid serious design flaws. 
The objective of this research is to assess the value of feasibility studies prior to 
PMOS implementation and highlight the importance of local physicians’ feed-
back. Methods: A feasibility study in 6 Eastern European countries was conducted 
via collection of physician surveys to assess local standard of care. The feasibility 
questionnaire was developed to assess operational aspects, such as availability of 
patient population, site experience and time and willingness to participate. The 37 
physicians who received the questionnaire were selected through PubMed; they 
were all experts who have published regarding HCV infection and were provided 
with the protocol synopsis Results: Out of the 37 selected physicians, 18 gastro-
enterologists, hepatologists, and infectious disease specialists in Bulgaria, Croatia, 
The Czech Republic, Hungary, Poland and Romania completed the questionnaire. 
The participating Physicians were working exclusively in public institutions. The 
average number of HCV patients seen by year is 140 and out of them 78 are treated 
by Interferon. They specified that they can enrol 2 eligible patients per month on 
average. They see their patients frequently during treatment initiation (bi-weekly 
or monthly). However, the follow-up varies from one country to another (quarterly 
or semi-annually). Physicians indicated that patient records and data regarding 
blood tests and procedures are accessible for 100% of the cases. Over 60% of the 
sites were familiar with Patient Reported Outcomes. Overall, 12 physicians were 
interested in participating in the Study. ConClusions: The result of this survey 
helped us documenting routine medical practice and confirming the study design 
and methodology to be implemented.
PRM217
uSe of SuRRogate outCoMeS In health teChnology aSSeSSMentS 
(htaS)
Jaksa A., Ho Y.S., Daniel K.
Context Matters, Inc., New York, NY, USA
objeCtives: This study analyzes how frequently surrogate outcomes are used 
in HTAs and if the validity of these outcomes are discussed and reported within 
the HTAs. A surrogate outcome is defined by the National Institutes of Health as 
a biomarker intended to substitute for a clinical endpoint. A surrogate outcome 
is used when a clinical endpoint of interest is not ideal or does not occur often 
enough to perform meaningful statistical analysis. It is appropriate to use a sur-
rogate outcome only when there is a strong correlation with the clinical endpoint. 
Before using surrogate outcomes researchers should confirm that the surrogate 
outcome is biologically plausible, has a magnitude of association with the clini-
cal endpoint, and reflects changes in the relevant clinical endpoint. Methods: 
Context Matters (CM) analyzed 1,056 HTAs spanning 38 disease conditions. Each 
HTA had a primary outcome that could be classified as either a surrogate outcome 
or a clinical endpoint. Data was analyzed for eight HTA agencies: AHRQ, DERP, 
SMC, HAS, PBAC, NICE, CADTH, and HIS Scotland. For those HTAs using a sur-
rogate outcome as the primary outcome, CM then determined if the HTA agency 
reported the use of the surrogate and/or discussed the surrogate outcome’s valid-
ity. Results: Ninety-one percent of HTAs used a surrogate outcome (966 HTAs), 
but only 11% (109 HTAs) identified it as a surrogate outcome and/or discussed 
its validity. The agencies that discussed the use of the surrogate outcome most 
often were AHRQ, DERP, and HIS Scotland at 48.1%, 28.6%, and 29.0% of the time, 
respectively. ConClusions: Surrogate endpoints are prevalent in HTAs, but the 
agencies rarely discuss the validity of these endpoints. All agencies failed to dis-
cuss the use of the surrogate endpoint in over 50% of their reviews. HTA agencies 
are not following best practice use of surrogate outcomes.
ReSeaRCh on MethodS – Conceptual Papers
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PRoPoSal of eConoMIC evaluatIon guIdelIne In JaPan
Fukuda T.1, Akazawa M.2, Fukuda H.3, Igarashi A.4, Ikeda S.5, Ishida H.6, Kobayashi M.7, 
Moriwaki K.8, Noto S.8, Sakamaki H.9, Saito S.10, Shimozuma K.11, Shiroiwa T.1, Takura T.12, 
Tomita N.13
1National Institute of Public Health, Saitama, Japan, 2Meiji Pharmaceutical University, Tokyo, 
Japan, 3Institute for Health Economics and Policy, Tokyo, Japan, 4Tokyo Univ. Faculty of Pharmacy, 
Tokyo, Japan, 5International University of Health and Welfare, Otawara City, Tochigi, Japan, 
in EMBASE and MEDLINE, search terms ‚hemophilia B‘ and ‚FIX‘. Inclusion crite-
ria: journal articles (JA), conference abstracts (CA), English language, published 
between January 2009 and March 2013, studies only. Screening of titles, abstracts 
and full texts was performed subsequently. Registered trials (RT) concerning HB 
or FIX were identified in ClinicalTrials.gov. Analysis comprised age group, spon-
sor, research topic, recruitment status, and study design. Results: Screening of 
1,639 hits yielded 31 JA describing 35 studies, and 62 CA. FIX was the topic of 21 
studies (60.0%) and 29 CA (46.8%). A total of 7 studies focused on various aspects 
of HB, 6 on haemophilia studies with separate data on HB. Gene therapy was the 
main focus of 2 JA and 11 CA (17.7%). Screening of 173 hits from ClinicalTrials.gov 
yielded 47 RT, 42 unpublished. Overall 32 unpublished RT (76.2%) concerned FIX, and 
4 (9.5%) gene therapy. Randomized study design was described in one study (2.9%) 
and 4 RT (9.5%), and 3 studies (8.6%) and 7 RT (16.7%) were prospective observa-
tional comparative. ConClusions: Randomized study design or comparator arms 
were uncommon, and payers’ requirements for evidence were not met. Therefore, 
randomization, comparison to standard of care and documentation of outcome 
should be discussed. Development of refined statistical methods and exploitation 
of complementary data like real-life data may help to fill actual evidence gaps in 
rare diseases.
PRM213
the Role of dSM In the eMa and fda authoRIzatIon PRoCeSS foR 
PSyChIatRIC dRugS
Meyers O.I.
Truven Health Analytics, Cleveland, OH, USA
objeCtives: In May 2013, the American Psychiatric Association released the fifth 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). This 
is significant for clinicians, researchers, and developers of psychopharmacologic 
drugs. The previous version of the DSM, the DSM-IV-TR, was published in 2000 and 
the last time the diagnostic criteria were revised was in 1994, when the DSM-IV 
was published. The objective of this review was to determine how much of a role 
DSM has played in the drug approval process in Europe and the US. Methods: For 
drugs authorized since 2000, summaries of product characteristics (SPCs; EMA) and 
approved labels (FDA) were reviewed to determine how frequently the DSM is men-
tioned in the “clinical particulars” or “indications” sections and how frequently DSM 
criteria are mentioned in the clinical trials sections of the SPCs or labels. The review 
focused on schizophrenia and psychotic disorders, mood disorders, and for the 
FDA, attention-deficit/hyperactivity disorder as well. Results: For EMA-authorized 
products, 8 EPARs met the criteria with 10 indications in total. The DSM was never 
mentioned in the indications or posology sections, but in 7 (70%) of the descriptions 
of pharmacodynamic properties (section 5.1), DSM criteria were cited as the study 
inclusion criteria. For FDA-approved products, 17 labels with 22 indications met the 
review criteria. The DSM was mentioned in 10 of the indications sections (45%) and 
DSM criteria were cited as inclusion criteria in 20 instances (91%). ConClusions: 
Regulators in Europe and the US rely heavily on DSM diagnostic criteria, in the 
sense that these often serve as inclusion criteria for pivotal clinical trials. Given 
significant changes to the criteria in many diagnostic categories, regulators and 
sponsors need to familiarize themselves with the document and evaluate their use 
of DSM criteria going forward.
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PodCaStS aS a leaRnIng tool In a ReSeaRCh MethodS CouRSe foR 
PhaRMaCy StudentS
Nguyen T.L., Lovett A.W., Lundquist L.M., Bonner C.L.
Mercer University College of Pharmacy and Health Sciences, Atlanta, GA, USA
objeCtives: Podcasts (recorded lectures) can be beneficial for all students, particu-
larly English as a second language students who face language barriers when learn-
ing in another language. There is limited study on pharmacy student perceptions 
and podcasts, none from an international perspective. The primary objective was 
to describe pharmacy students’ perceptions on the usefulness of podcasting and a 
secondary objective was to compare perceptions between native versus non-native 
English speakers in a pharmacy research course. Methods: All first year phar-
macy students (n= 157) attending a Research Methods course in 2012 were invited 
to participate in a survey, which utilized a 4-point Likert Scale (1= strongly disagree, 
2= disagree, 3= agree, and 4= strongly agree). Podcasts covered all course topics such 
as Applied Statistics, Odds Ratio and Relative Risk, Case Reports, Observational 
Studies, Randomized Controlled Trials, and Economic Evaluations. Descriptive sta-
tistics and t-tests were utilized to analyze the data in SPSS. The study was approved 
by the Institutional Review Board. Results: A total of 73% of the class completed 
the survey (40.2% Caucasian, 32% Asian and 25% African American). A total of 24.1% 
identified themselves as non-native English speakers, 94.6% lived in the US for 
greater or equal to 5 years and 66.1% communicated in English at home. The major-
ity of students agreed/strongly agreed that podcasts helped them to prepare for 
exams (92.9%), podcasts were a useful learning tool (91.2%), promoted understand-
ing of course material (89.3%), helped with missed concepts (96.4%), and facilitated 
note-taking at their own pace (92.2%) with mean scores 3.34, 3.27, 3.27, 3.48 and 3.48, 
respectively. Results of the t-test revealed that there is no statistically significant 
difference between native versus non-native English speaking students in their 
perceptions of podcast usefulness (p> .05). ConClusions: Podcasts are beneficial to 
a majority of students, despite their language background. Podcasts have the poten-
tial to be a valuable learning tool for students taking a research methods course.
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gRade foR qualIty aSSeSSMent of effICaCy and effeCtIveneSS 
StudIeS on antI-tnfS tReatMent of RheuMatoId aRthRItIS
Taino B, Nobre M.R.C
INCOR - HCFMUSP, Sao Paulo, Brazil
objeCtives: Assess the quality of evidence on experimental and observational clini-
cal research through the same approach named GRADE (Grading of Recommendations 
